Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma - Top-Institutions - MDSpire

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • By

  • Eric Jurgens

  • Tala Shekarkhand

  • Colin Rueda

  • David Nemirovsky

  • Andriy Derkach

  • Ross S. Firestone

  • Kevin Miller

  • Bruno Almeida Costa

  • Sridevi Rajeeve

  • Alexander M. Lesokhin

  • Neha Korde

  • Carlyn R. Tan

  • Hamza Hashmi

  • Hani Hassoun

  • Kylee Maclachlan

  • Urvi A. Shah

  • Malin Hultcrantz

  • Issam Hamadeh

  • Sergio A. Giralt

  • Gunjan L. Shah

  • Heather J. Landau

  • Michael Scordo

  • Saad Z. Usmani

  • Sham Mailankody

  • Zainab Shahid

  • November 1, 2025

  • 0 min

Share

Top Institutions in Hematology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Hematology/Oncology
    • Infectious Diseases
    • Immunotherapy

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Hematology/Oncology
    • Infectious Diseases
    • Immunotherapy

  • #3

    Mayo Clinic
    Mayo Clinic

    Rochester, MN

    Key Differentiators

    • Hematology/Oncology
    • Infectious Diseases

  • #4

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Hematology/Oncology
    • Infectious Diseases
    • Transplant Infectious Diseases

Original Source(s)

Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

  • by Eric Jurgens, Tala Shekarkhand, Colin Rueda, David Nemirovsky, Andriy Derkach, Ross S. Firestone, Kevin Miller, Bruno Almeida Costa, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn R. Tan, Hamza Hashmi, Hani Hassoun, Kylee Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam Hamadeh, Sergio A. Giralt, Gunjan L. Shah, Heather J. Landau, Michael Scordo, Saad Z. Usmani, Sham Mailankody, Zainab Shahid

  • November 1, 2025

Related Content

Assessment of the Safety and Effectiveness of CD38-Targeted CAR-T Cell Therapy in Treating Multiple Myeloma: A Systematic Review and Meta-Analysis

The 2024 EBMT activity report: crossing one million HCTs and 20,000 CAR-T. A landmark in cellular therapy

Proteomic and Metabolomic Profiling via Mass Spectrometry in Multiple Myeloma: A Comprehensive Review of Prognostic Biomarkers and Monitoring of Minimal Residual Disease